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Abstract
Background: Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, known as statins, are commonly used
as cholesterol-lowering drugs. During the past decade, evidence has emerged that statins also have
neuroprotective effects. Research in the retina has shown that simvastatin, a commonly used statin, increases Akt
phosphorylation in vivo, indicating that the PI3K/Akt pathway contributes to the protective effects achieved. While
research about neuroprotective effects have been conducted in several systems, the effects of statins on the inner
ear are largely unknown.
Results: We evaluated whether the 3-hydroxy-3-methylglutaryl-coenzyme A reductase is present within the rat
cochlea and whether simvastatin is able to protect auditory hair cells from gentamicin-induced apoptotic cell
death in a in vitro mouse model. Furthermore, we evaluated whether simvastatin increases Akt phosphorylation in
the organ of Corti. We detected 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in organ of Corti, spiral
ganglion, and stria vascularis by reverse transcriptase-polymerase chain reaction (RT-PCR). Moreover, we observed a
dose-dependent and significant reduction of hair cell loss in organs of Corti treated with simvastatin in addition to
gentamicin, as compared to samples treated with gentamicin alone. The protective effect of simvastatin was
reversed by addition of mevalonate, a downstream metabolite blocked by simvastatin, demonstrating the
specificity of protection. Finally, Western blotting showed an increase in organ of Corti Akt phosphorylation after
simvastatin treatment in vitro.
Conclusion: These results suggest a neuroprotective effect of statins in the inner ear, mediated by reduced 3-
hydroxy-3-methylglutaryl-coenzyme A reductase metabolism and Akt activation.
Background
Until recently, sensorineural hearing loss due to damage
to cochlear hair cells (HC) has been regarded as an inevi-
table consequence of age, genetic conditions or exposure
to certain environmental stimuli. During the past several
years, some of the critical intracellular events that med-
iate damage to HCs have been discovered, using amino-
glycoside-induced HC death in vitro as a model [1-4]. It
has been demonstrated that small GTPases, such as Ras
and Rho/Rac/Cdc42, as well as the c-Jun-N-terminal
kinase signalling pathway, are activated in cells exposed
to the drug and that phoshatidylinositol-3-kinase (PI3K)
signalling mediates HC survival and opposes gentamicin
toxicity via its downstream target, the protein kinase
AKT [5-9]. After prolonged aminoglycoside exposure,
caspases are activated and HCs undergo apoptotic cell
death [10,11].
Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, otherwise known as statins, are
commonly used as cholesterol-lowering drugs. Statins
reduce the incidence of primary and secondary coronary
heart disease in clinic trials and act by blocking the
enzyme necessary for the production of L-mevalonate, an
intermediary product in the synthesis of cholesterol
[12,13]. During the past decade, evidence has emerged
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models suggest that statins may be beneficial in the treat-
ment of multiple sclerosis and during acute stroke
[14-20]. Several in vitro and in vivo studies provided evi-
dence that statins activate the protein kinase B (PKB/
A k t )p a t h w a y[ 2 1 , 2 2 ] .W o r kd o n ei nt h er e t i n ah a s
shown that simvastatin, a commonly used statin,
increases Akt phosphorylation in vivo, indicating that the
PI3K/Akt pathway contributes to central nervous system
protective effects achieved [23].
In the inner ear, Cai et al. found that simvastatin pro-
tected the hearing of mice deficient in apolipoprotein E
that were fed a high fat diet [24]. However, they attributed
this effect to control of hyperlipedemia. Syka et al. demon-
strated that atrovastin slows down the deterioration of
inner ear function with age in mice. They suggested that
atrovastin reduces endothelial inflammatory effects that
influence the blood supply to the inner ear [25]. While no
experiments were performed, Borghi et al. hypothesized
that statins might be useful as a treatment for sensori-
neural hearing loss due to their metabolic and hemody-
namic effects [26]. However, a prospective, randomized,
double-blinded clinical trial by Olzowy et al. did not show
an effect of atrovastin on progression of sensorineural
hearing loss in the elderly [27]. In contrast, Chiu et al.
reported that simvastatin exposure produced damage to
lateral line HCs in the zebrafish, although the mechanism
was not identified [28].
Given these conflicting data, we determine whether or
not HMG-CoA reductase is present within the rat cochlea,
and whether simvastatin is able to protect mammalian
auditory HCs from gentamicin-induced HC death. Given
the results of Chiu et al. we also evaluated simvastatin for
HC toxicity [28]. In addition we investigated the metabolic
pathway involved in simvastatin effects, and whether this
drug increases Akt phorphorylation in the organ of Corti
(OC).
Results
HMG-CoA reductase mRNA is expressed in the cochlea
HMG-CoA mRNA were detected in the OC, spiral gang-
lion (SG), and stria vascularis (SV) using specific primer
sets (Table 1). The amplification of b-actin confirmed a
successful synthesis of cDNA. The specificity of the
designed primers was confirmed using cDNA from rat
brain tissue. One single band of the correct size for every
tissue was observed (Figure 1). Omission of cDNA in the
PCR mixture served as negative control.
Simvastatin has no toxic effect on HCs and protects HCs
from gentamicin-induced HC damage in vitro
To exclude a toxic effect of simvastatin, the OCs were
cultured with the highest dosages used in this study
(100 μM) for 72 hours. The number of HCs was com-
pared between cultured OCs in presence and absence of
simvastatin. Because no difference was found, a toxic
effect of simvastatin was excluded. Untreated control
OCs and those treated with simvastatin showed three
orderly rows of outer hair cells (OHCs) and a single row
of inner hair cells (IHCs) (Figure 2).
As expected, gentamicin treatment led to a loss of
HCs (Figure 2). Treatment with both gentamicin and
simvastatin at the concentration of 1 μM significantly
increased OHC survival in the middle and basal
cochlear turn (Figure 3). Whereas treatment with both
gentamicin and simvastatin at the concentration of 10
μM and 100 μM, resulted in increased OHC survival in
all cochlear turns (Figure 3). The protective effect of
simvastatin on gentamicin-induced HC damage was
dose dependent in the middle and basal turn (Figure 3).
Mevalonate does not effect gentamicin-induced HC
damage in vitro and has no toxic effect on hair cells in
vitro itself
To exclude a toxic effect of mevalonate, the OCs were cul-
tured with the dosages used in this study (100 μM) for 72
hours. The number of HCs was compared between cul-
tured OC in presence and absence of mevalonate. Because
no difference was found, a toxic effect of mevalonate was
excluded. Untreated control OCs and those treated with
mevalonate alone showed three orderly rows of OHCs and
a single row of IHCs (Figure 2). Treatment with gentami-
cin and mevalonate showed no statistically significant dif-
ference in OHC survival compared to treatment with
gentamicin only in all cochlear turns (Figure 3).
Mevalonate reverses the protective effect of simvastatin
on gentamicin-induced HC damage in vitro
Treatment with simvastatin 10 μM in addition to genta-
micin showed significantly less OHC loss in all cochlear
turns than groups treated with gentamicin only or with
simvastain 10 μM and mevalonate 100 μMi na d d i t i o n
Table 1 Primer sequences used for HMG-CoA reductase and b-actin
Gene Primer name Sequence 5’ ® 3’ Annealing temperature Exons Product length
HMG-CoA reductase Forward TGTTCAAGGGGCGTGCAAAGACAA 63 17 202 bp
Reverse TCAAGCTGCCTTCTTGGTGCATGT 18
b-actin Forward ACGGTCAGGTCATCACTATCGGCA 58 3 208 bp
Reverse ATCCTGTCAGCAATGCCTGGGT 4
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Page 2 of 10to gentamicin (Figure 3). The protective effect of sim-
vastatin was reversed by the addition of mevalonate, a
downstream metabolite. This bypasses the effect of sim-
vastatin on the upstream enzyme, 3-hydroxy-3-methyl-
glutaryl-coenzyme A, demonstrating the mechanism of
protection.
Simvastatin increases Akt phosphorylation in vitro
Western blotting revealed specific activation of Akt in
OC treated with simvastatin in vitro (Figure 4). Blots
using anti-pAkt revealed a strong increase in activated
Akt, after a 1 hour exposure to 10 μM simvastatin. p-Akt
has been referenced to total Akt in the control and sim-
vastatin treated group (Figure 4).
Discussion
At present, little is known about the effects of statins on
the inner ear. It has been hypothesized that statins might
be useful as a treatment for sudden sensorineural hearing
loss due to their metabolic and hemodynamic effects [26].
Syka et al. demonstrated that atrovastin had a positive
effect on the deterioration of inner ear function with age
in mice by analysing distortion product otoacoustic emis-
sions (DPOAE). Treated mice showed decreased expres-
sion of intracellular and vascular adhesion molecules in
the aortic wall and the authors suggest that reduced
endothelial inflammatory effects may contribute to better
OHC survival by influencing blood supply to the inner ear
[25]. While Syka et al. attribute the positive effect of statins
on inner ear function on hemodynamic effects, other
reports suggest that statins act through their metabolic
effects. It has been reported that simvastatin may prevent
hearing loss and inner ear damage in apolipoprotein E
gene knockout mice fed a high-fat diet, by reducing ather-
osclerotic lesions and levels of glucose, cholesterol, low
density lipoproteins, and triglyceride [24]. Therefore it was
suggested that statins might be used to treat hearing loss
associated with hyperlipedemia.
Toxic effects of simvastatin on the inner ear have also
been reported. Park et al. found that simvastatin treatment
induced morphological alterations and apoptosis in mur-
ine cochlear neuronal cells [29]. Chiu et al. reported that
simvastatin was toxic to lateral line HCs in the zebrafish
[28]. Given these conflicting data, we evaluated the effects
of simvastatin on cochlear HCs in vitro. We demonstrate
that HMG-CoA reductase mRNA is expressed in the
cochlea. We excluded a toxic effect of simvastatin expo-
sure on auditory HCs. Treatment with simvastatin in addi-
tion to gentamicin led to significant decrease in HC loss
compared with the gentamicin group. Although simvasta-
tin enhanced HC survival, it did not provide complete pro-
tection against gentamicin-induced HC loss. Western
blotting reveals that simvastatin increased Akt phosphory-
lation in the OC in vitro, indicating that the PI3K/Akt
pathway may contribute to the protective effects achieved.
It is significant that the protective effect of simvastatin was
reversed by addition of mevalonate, since this finding
demonstrates the specificity of protection to the metabolic
pathway that is regulated by statins.
It should be noted that in our experiments cochlear
explants were harvested from postnatal day 3-5 animals
since only newborn animals can be used for extended cul-
ture of inner ear HCs. Adult HCs do not survive in cul-
ture. In a large number of studies, aminoglycosides have
been utilized as inducers of HC death and the immature
cochlea is an established in vitro model. However, younger
animals are more sensitive to ototoxins [3,4,7] and there-
fore our results must generalize to adults with caution. It
should be noted that for the RT-PCR and Western blot-
ting experiments we used Wistar rat pups, whereas for the
in vitro experiment transgenic mouse pups in which
expression of green fluorescent protein (GFP) is driven by
an auditory HC specific promoter were used. The rationale
for this is that the larger cochlea of the rat allows more tis-
sue to be harvested and fewer animals needed to be sacri-
ficed for the experiments. The transgenic mouse pups
were chosen for the in vitro experiments in order to easily
visualize the GFP-positive HCs, and to monitor HC loss
while the cells were alive.
The possibility that simvastatin might interact physi-
cally with gentamicin must also be considered. Although
we have no direct evidence excluding physical interac-
tion, the fact that the protective effect of simvastatin on
gentamicin-induced HC loss was reversed by adding
mevalonate argues against it.
How can the protective effect of simvastatin in genta-
micin-induced HC loss be explained? To date there are
no reports of simvastatin-induced intracellular events on
HCs available. Certain evidence suggests that the reduc-
tion of cholesterol cannot entirely account for statins’
200 bp
B SG OC SV
ȕ-actin: 208 bp
NTC
200 bp
NTC SG OC SV
HMG-CoA: 202 bp
B M
M
Figure 1 Detection of HMG-CoA reductase in the cochlea of 5-
day-old Wistar rats. Total RNA of the organ of Corti (OC), the
spiral ganglion (SG) and the stria vascularis (SV) was reversed
transcribed into cDNA and amplified by PCR. Total brain (B) RNA
served as a positive control. Omission of cDNA in the PCR mixture
served as no template control (NTC). The DNA ladder (M) is
indicated with its lengths. b-actin was used to control cDNA
synthesis.
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that short-term statin treatment does not alter choles-
terol level in the brain. This indicates that statins have
another mechanism of action, possibly through the
other products of the mevalonate pathway that play a
role in cellular signalling [30,31]. This is not surprising
since mevalonate is not only essential for the biosynth-
esis of cholesterol, but also for other products, such as
Coenzyme Q10 (Q10) and isoprenylated proteins, which
are essential in several cell processes [22,32].
Several in vitro and in vivo studies provided evidence
that statins activate the PKB/Akt pathway [21,22]. Work
done in the retina has shown that simvastatin increases
Akt phosphorylation in vivo, indicating that the PI3K/
Akt pathway contributes to the central nervous system
protective effects achieved [26]. In a previous study, we
demonstrated that PI3K mediates HC survival and
opposes gentamicin toxicity in neonatal rat OC [9].
Therefore, activation of Akt by simvastatin as demon-
strated here is one explanation for the protective effects
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Figure 2 Effect of simvastatin on gentamicin-induced hair cell damage. Photograph of organs of Corti (OCs). Overview on the left (scale bar
100 μm) and high magnification on the right (sale bar 20 μm). Untreated OCs (A), OCs exposed to 100 μM simvastatin (B), and OCs exposed to
100 μM mevalonate demonstrate three orderly rows of outer hair cells (OHC) and a single row of inner hair cells (IHC). OCs cultured with
gentamicin showed significant loss of hair cells (C). Treatment with increasing concentrations of simvastatin in addition to gentamicin resulted in
dose dependent significant decrease in hair cell loss compared with gentamicin treatment only (D-F). Mevalonate reverses the protective effect
of simvastatin on gentamicin-induced hair cell damage. OCs cultured with mevalonate in addition to gentamicin and OCs cultured with
simvastatin 10 μM and mevalonate showed the same degree of hair cell loss as OCs cultured with gentamicin only (H,I).
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Page 4 of 10of the drug on gentamicin-induced HC loss. A study on
mammalian endothelial cells demonstrated that simvas-
tatin activates Akt in these cells, while treatment with
mevalonate blocked this activation of Akt [22]. This
finding directly links HMGCoA reductase -mevalonate
metabolism to Akt activation. Our study is the first
demonstration, to our knowledge, that this pathway is
involved in Akt activation in the inner ear.
A second potential mechanism through which statins
can affect cells is by blocking the isoprenylation of small
G proteins, such as Ras and Rho/Rac/Cdc42. It has been
shown that statins downregulate the activity of small G
proteins in cardiomyocytes in culture and in vivo [33].
In previous studies, we showed that inhibition of the
small GTPases Rho/Rac/Cdc42 or specific blocking of
Ras provided potent protection against gentamicin-
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Figure 3 Quantitative analysis of surviving outer hair cells (OHCs) by cochlear turns. Data are expressed as the mean number of surviving
OHCs per 20 IHCs. Vertical lines represent SEM. A) Average OHC survival in the apical turn in the different experimental conditions. There was a
statistically significant increase in OHC survival between the groups treated with simvastatin in the concentration of 10 μM and 100 μMi n
addition to gentamicin compared with gentamicin treatment only (p < 0.05). * indicates significant difference from gentamicin treatment only.
B) Average OHC survival in the middle turn in the different experimental conditions. There was a statistically significant increase in OHC survival
between the groups treated with simvastatin in addition to gentamicin compared with gentamicin treatment only (p < 0.05 simvastatin 1 μM, p
< 0.01 simvastatin 10 μM and simvastatin 100 μM). The protective effect of simvastatin was dose dependent. * indicates significant difference
from gentamicin treatment only. + indicates significant difference between the indicated groups (p < 0.01).C) Average OHC survival in the basal
turn in the different experimental conditions. There was a statistically significant increase in OHC survival between the groups treated with
simvastatin in addition to gentamicin compared with gentamicin treatment only (p < 0.05 simvastatin 1 μM, p < 0.01 simvastatin 10 μM and
simvastatin 100 μM). The protective effect of simvastatin was dose dependent. * indicates significant difference from gentamicin treatment only.
+ indicates significant difference between the indicated groups (p < 0.01).
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Page 5 of 10induced auditory HC loss [5,6]. Since mevalonate alone
does not affect HC death, this implies that sufficient
prenylated Ras is normally present in HCs, and that
additional mevalonate does not enhance damage signal-
ing. However, we did not evaluate the role of small G
proteins in this study. Our conclusions on the protective
effect of simvastatin in gentamicin-induced HC loss are
summarized in Figure 5.
As mentioned above, simvastatin has been shown to
h a v eat o x i ce f f e c to nf i s hl a t e r a ll i n eH C sa n dc o c h l e a r
neurons [28,29]. The concentration of simvastatin used in
this study is in the same range used on cochlear neurons
[29]. Although this prior work did not address mammalian
HCs, potential toxic effects need to be considered. Meva-
lonate is essential for the production of coenzyme Q10
and statins lead to a dose-dependent reduction in Q10
[34]. Q10 is an important mitochondrial antioxidant that
helps bypass existing mitochondrial respiratory chain
defects. Mitochondrial predispositions and dysfunction are
thought to play a major role in adverse effects of statins,
and it has been demonstrated that water-soluble Q10 pro-
motes OHC survival in a guinea pig model of noise
induced hearing loss [35,36]. We hypothesize that zebra-
fish HCs and mouse cochlear neurons might be more vul-
nerable to Q10 reduction by simvastatin than mouse
cochlear HCs. While this hypothesis is perhaps too com-
plex to be attractive without additional supporting data, it
is at least consistent with our observations and with the
current literature.
Conclusion
Our results demonstrate a partial protection of OHCs in
the OC against gentamicin ototoxicity in vitro. This
neuroprotective effect of statins on mammalian auditory
HCs is mediated by reduced 3-hydroxy-3-methylglu-
taryl-coenzyme A reductase metabolism and Akt
activation.
Methods
Animal procedures
The animal procedures for the RT-PCR were carried out
in Basel, Switzerland according to an approved animal
research protocol (Kantonales Veterinäramt, Basel, Swit-
zerland) in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC).
All other animal procedures were carried out in San
Diego, CA USA. The local animal subject committee of
the VA San Diego Healthcare System approved the ani-
mal procedures in accordance with the guidelines laid
down by the National Institute of Health regarding the
care and use of animals for experimental procedures.
Tissue extraction
For RT-PCR and western blotting tissue was extracted
from 5-day-old Wistar rat pups (Harlan, Indianapolis, IN,
USA). For all other experiments 3-day-old transgenic
mice pups in which expression GFP is driven by an audi-
tory HC specific Brn-3.1 promoter were used [37]. The
animals were decapitated, and cochlear microdissections
were performed under a light microscope to isolate the
O C ,t h eS G ,a n dt h eS V[ 3 8 ] .B r a i nt i s s u ew a sr e m o v e d
from the same animals as a positive control for the RT-
PCR. During the microdissection, the different tissues
were maintained in ice-cold PBS.
Tissue culture
For experiments in which cultures of OCs were needed,
OCs were first incubated in culture medium [Dulbecco’s
Modified Eagle Medium supplemented with 10% FCS,
25 mM HEPES and 30 U/ml penicillin (Invitrogen, Carls-
bad, CA, USA) at 37°C in 5% CO2] and left for 24 hours at
37°C in 5% CO2 for recovery. After that period, the OCs
were transferred into a new solution and incubated for
48 hours at 37°C in 5% CO2. To induce HC damage, OCs
were cultured with 50 μM gentamicin (Sigma-Aldrich, St.
Louis, MO, USA) in cell culture medium for 48 hours.
OCs were pretreated for 24 hours with increasing amounts
of simvastatin (Sigma-Aldrich) at the final concentration
of 1 μM, 10 μMo r1 0 0μM in the cell culture medium,
mevalonate 100 μM in cell culture medium and with sim-
vastatin 10 μM in combination with mevalonate 100 μM
in cell culture medium during the 24 hour recovery period
after dissection. Before use simvastatin was converted into
the active acid following the protocol of Bogman et al.
[39]. Stock solutions of 10 μM simvastatin in DSMO were
stored at - 20°C. After this pretreatment, OCs were
exposed either to gentamicin and simvastatin for 48 hours
or to gentamicin in combination with simvastatin and
mevalonate for 48 hours. Other OCs were either held in
culture medium alone (control), treated with simvastatin
at a final concentration of 100 μMo rw i t hm e v a l o n a t ea ta
final concentration of 100 μM.
pͲAkt
ControlSimvastatin
TotalAkt
Figure 4 Representative Western blots of phosphorylated Akt
and total Akt. Organs of Corti were either exposed for 1 hour to
control media (Control) or media containing 10 μM simvastatin
(Simvastatin).
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Anti-apoptotic
Events
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Protein
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Figure 5 A simplified model of signal transduction in gentamicin-induced hair cell damage and the mechanisms of statin-mediated
protection. The mode of initial interaction between the HC and gentamicin is not known. It may include a receptor, and/or entry of gentamicin
into the cell followed by generation of reactive oxygen species (ROS). We propose that statins act by enhancing Akt activiation and decrease the
isoprenylation of small G proteins, such as Ras and Rho/Rac/Cdc42.
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For PCR, 20 OCs, SGs, SVs and 20-40 mg brain of 5-
day-old WS rat pups were separately placed in RNAlater
(Qiagen, Hombrechtikon, Switzerland). RNA isolation of
brain and inner ear components were performed using
the RNAeasy Minikit (Qiagen) including DNase treat-
ment according to the supplier’s instructions. To homo-
genize the tissues, we used homogenizer Ultra-Turrax
T8 (IKA-Werke, Staufen, Germany). The quantity and
quality of the isolated RNA was determined with Nano-
Drop ND 1000 (NanoDrop Technologies, Delaware,
USA). The 260/280 nm ratio of all our samples was
between 1.8 and 2.1.
Primer design
Gene sequences from HMG-CoA reductase
(NM_013134.2) and b-actin (NM_031144.2) were accessed
from GenBank. Primers for RT-PCR were designed using
Primer-Blast software available at the NCBI (National
Center for Biotechnology Information). Our criteria for
primer design included Tm values between 58°C and 60°C,
a minimum length of 20 nt, a product size of 100-500 bp,
with an absence of long G-C stretches. Primers were
designed to cross at least one exon junction for the speci-
fic amplification of cDNA and to avoid amplification of
genomic DNA. The details of primers employed along
with the annealing temperatures and product sizes are
provided in Table 1.
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA (1 μg) was reverse transcribed into cDNA with
the first-strand cDNA synthesis kit (Roche Applied Bios-
ciences, Rotkreuz, Switzerland) according to the supplier’s
instructions. PCR was performed using the PCR Master
Mix (Roche Applied Biosciences) with primers specific for
HMG-CoA reductase. b-actin primers were used as a posi-
tive control for cDNA synthesis. The primer sets are
described in Table 1. PCR reactions were run in the
Eppendorf Mastercycler (Eppendorf, Hamburg, Germany)
under the following conditions. For HMG-CoA reductase,
we started with an initial denaturation of 94°C for 3 min-
utes and followed by 30 cycles. Each cycle consisted of
denaturation at 94°C for 30 seconds, annealing at 63°C for
30 seconds and extension at 72°C for 30 seconds, with a
final extension step at 72°C for 5 minutes. For b-actin, we
started with an initial denaturation of 94°C for 3 minutes
and followed by 30 cycles. Each cycle consisted of dena-
turation at 94°C for 30 seconds, annealing at 58°C for 45
seconds and extension at 72°C for 30 seconds, with a final
extension step at 72°C for 1 minute. The PCR products
were stained with SybrGreen I (Molecular Probes, Oregon,
USA), separated by electrophoresis on a 2% agarose gel
and visualized under UV light. Omission of cDNA in the
PCR mixture served as negative control.
Hair cell count
OCs were fixed in 4% paraformaldehyde. After fixation,
the OCs were visualized and photographed using a fluor-
escence microscope (Olympus FSX100). Quantitative ana-
lysis was obtained by evaluating 60 OHCs associated with
20 IHCs in a given microscope field. Explants were ana-
lyzed separately for the apical, middle and basal turn. For
each turn, two random microscope fields were counted
and averaged. These values were averaged across the six
replications of each experiment. Since there was almost no
damage to the IHCs (< 5%), only the OHCs were counted
and used to analyze HC survival.
Results obtained in the HC counting were analyzed by
using analysis of variance (ANOVA) followed by the least
significant difference (LSD) post-hoc test (Stat View 5.0).
Differences associated with P-values of less than 0.05
were considered to be statistically significant. All data are
presented as mean ± SD.
Assessment of Signaling Protein Activation
To assess the activation of the PIK3/Akt signaling path-
way, per condition 6 intact OCs from 5-day-old Wistar
rat pups (Harlan) were harvested and placed in cell cul-
ture media for 24 hours as described above. They were
then placed in cell culture media, with or without 10
μg/ml simvastatin for 1 hour. Explants were collected
from media, and lysed with 100 μl T-Per Tissue Protein
Extraction Reagent (Thermo Scientific, Rockford, IL,
USA) in 1X phosphatase/proteases inhibitors (Roche,
Indianapolis, IN, USA) and sonicated for 10 min to
shear chromosomal DNA. Samples where centrifuge at
10,000G for 10 minutes to separate cytosolic part from
membranous components. Equal quantities of these
lysates were separated by Bis-Tris Mini Gels 4-12% gels,
and electrotransferred to polyvinylidene difluoride mem-
branes (Bio-Rad, Hercules, CA, USA). The membranes
were blocked with 5.5% nonfat dried milk in TBS-
Tween [50 mM Tris-HCL (pH 7.4), 150 mM NaCl,
0.05% Tween 20] for 60 min at room temperature. Blots
were incubated with primary antibodies in blocking buf-
fer overnight at 4°C and then incubated with horserad-
ish peroxidase-linked secondary antibodies (Jackson
Immuno, West Grove, PA, USA) followed by chemilu-
minescent detection (GE Healthcare, Piscataway, NJ,
USA). Blots were evaluated with antibodies against the
phosphorylated forms of Akt, and total Akt (both Cell
Signaling Technology, Beverly, MA, USA) on the same
membrane. Western blotting was replicated three times
with independent biological replicas.
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